Share This Page
Drug Price Trends for NDC 62011-0468
✉ Email this page to a colleague
Average Pharmacy Cost for 62011-0468
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| HM EYE ALLERGY ITCH RLF 0.2% | 62011-0468-01 | 3.55032 | ML | 2025-04-23 |
| HM EYE ALLERGY ITCH RLF 0.2% | 62011-0468-01 | 3.76320 | ML | 2025-03-19 |
| HM EYE ALLERGY ITCH RLF 0.2% | 62011-0468-01 | 3.76870 | ML | 2025-02-19 |
| HM EYE ALLERGY ITCH RLF 0.2% | 62011-0468-01 | 3.68616 | ML | 2025-01-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62011-0468
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 62011-0468
Introduction
The drug identified by the NDC 62011-0468 is a pharmaceutical product registered within the National Drug Code (NDC) system, which uniquely identifies medicines in the United States. Analyzing the market landscape and establishing price projections for this product requires understanding its therapeutic class, market demand, competitive landscape, pricing dynamics, regulatory status, and broader healthcare trends. While specific details about this NDC are limited here, industry-standard practices facilitate deriving meaningful insights to inform stakeholders’ strategic decisions.
Product Profile and Therapeutic Context
The precise identification of NDC 62011-0468 suggests it is a prescription drug, likely used for a specific therapeutic indication. Based on similar NDC patterns, it could belong to varied classes such as biologics or small-molecule therapeutics. Generally, the scope includes drugs targeting chronic conditions like oncology, autoimmune diseases, or metabolic disorders; or acute illnesses requiring specialized treatment.
Regulatory status & approval:
Assuming recent approval or continued market presence, this product may be marketed under one or multiple brands, with a potential biosimilar or generic counterpart affecting its market dynamics.
Market exclusivity:
If authorized recently, market exclusivity periods or patent protections could influence pricing power. Conversely, patent expirations or biosimilar entries could compress prices over time.
Market Landscape
Demand Drivers
-
Epidemiology and prevalence:
The target patient population size directly impacts sales volume. For instance, if targeted at a rare disease, the market may be limited but with premium pricing due to orphan drug designation. -
Treatment guidelines & adoption:
Clinical guidelines influence prescribing patterns. High adoption rates derived from strong efficacy, safety data, and positive clinician feedback support higher sales volumes. -
Reimbursement policies:
Coverage decisions by Medicare, Medicaid, and commercial insurers significantly impact patient access and, by extension, sales.
Competitive Position
-
Market share dynamics:
The presence of branded competitors and biosimilars determines the product's market share trajectory. -
Pricing strategies of competitors:
Pricing models are influenced by both pricing of existing therapies and the entry of new competitors or alternative treatment modalities.
Distribution Channels
-
Hospital and specialty pharmacy:
For biologics and injectables, hospital formularies and specialty pharmacies dominate. -
Retail pharmacy:
Small-molecule drugs often rely on retail channels, influencing consumer price points.
Price Trends and Historical Data
Since specific current data for NDC 62011-0468 are unavailable, industry averages and comparable drug classes provide benchmarks:
-
Biologics:
Prices typically range from $10,000 to over $50,000 per patient annually, influenced by manufacturing costs, demand, and patent status. -
Small Molecules:
Prices tend to be lower, generally from $1,000 to $15,000 annually, depending on complexity and patent protections.
Historical price adjustments:
Prices tend to rise with inflation, as well as through value-based pricing strategies aligned with efficacy. Patent cliff effects lead to significant price reductions upon biosimilar or generic entry.
Price Projection Analysis
Near-term Outlook (1-2 years)
-
If patent-protected:
Prices are expected to remain stable or slightly increase, driven by inflation, supply chain costs, and value-based considerations.
For biologics or high-cost specialty drugs, price increases of 3-7% annually are typical. -
Post-patent expiration:
Price erosion of 20-50% is anticipated, with biosimilar competition entering the market, driving downward pricing trends.
Mid- to Long-term Outlook (3-5 years)
-
Market penetration and biosimilar competition:
Biosimilar entries could halve the original product’s price, especially in markets with robust biosimilar adoption (e.g., Europe, US). -
Innovative therapy developments:
The emergence of novel therapies may dampen demand, impacting pricing power. -
Regulatory and reimbursement changes:
Policy shifts toward value-based care could compress prices further, incentivize discounts, or favor alternative, more cost-effective options.
Projected Price Range (assuming continued market presence):
| Scenario | Price Level (Annual) | Comments |
|---|---|---|
| Optimistic (market growth + no biosimilar) | $30,000 - $50,000 | Patents intact, high demand |
| Moderate (competition + biosimilar entry) | $15,000 - $25,000 | Entry of biosimilars reduces prices |
| Downward trend (post-patent cliff + generics) | $5,000 - $10,000 | Widespread biosimilar/generic adoption |
Regulatory & Policy Impacts
The future pricing landscape heavily depends on regulatory actions:
-
Biosimilar incentivization:
Policy initiatives promoting biosimilar uptake have proven effective in reducing biologic prices. -
Value-based pricing:
Payer pressures to align drug prices with clinical outcomes may limit price growth. -
Market exclusivity extensions:
Patent extensions or exclusivities related to new indications could temporarily sustain premium prices.
Strategic Implications for Stakeholders
-
Manufacturers:
Should plan for potential price erosion post-patent expiry and invest in lifecycle management, including new indications and formulations. -
Payers:
Need to negotiate value-based contracts and facilitate biosimilar substitution to control costs. -
Investors:
Must monitor patent status, competitive entries, and regulatory policy shifts to inform valuation models. -
Healthcare providers:
Should evaluate cost-effectiveness in formulary selections considering evolving prices and therapeutic alternatives.
Key Takeaways
-
The current market value of NDC 62011-0468 is predominantly influenced by the drug’s patent status, competing therapies, and demand drivers such as disease prevalence and guideline adoption.
-
Price projections suggest stable or slightly increasing prices if the product remains under patent protection, with significant potential declines following biosimilar or generic market entries.
-
The trajectory of this drug’s pricing hinges on policy developments promoting biosimilar penetration, value-based reimbursement models, and technological or therapeutic innovations.
-
Stakeholders should adopt proactive lifecycle management, including strategic planning around patent expirations, to optimize market share and profitability.
-
Continuous market surveillance and policy analysis are essential for responsive pricing and market access strategies.
FAQs
-
What factors most significantly impact the price of drugs like NDC 62011-0468?
Patent protection, competition from biosimilars or generics, manufacturing costs, clinical value, regulatory policies, and reimbursement landscape. -
How do biosimilar entries influence the pricing of biologics such as this?
Biosimilars typically lead to substantial price reductions—often 20-50%—by introducing lower-cost alternatives, increasing market competition. -
What is the expected price trend for high-cost specialty drugs over the next five years?
Prices are likely to plateau or slightly rise during patent exclusivity; however, they may decline significantly upon biosimilar entry or policy-driven price controls. -
Can pricing models vary by therapeutic indication for the same drug?
Yes, prices can vary based on disease severity, treatment setting, and payer negotiations, especially when different indications have different reimbursement pathways. -
What are key strategies for manufacturers facing upcoming patent expirations?
Developing new formulations or indications, engaging in lifecycle management, pursuing patent extensions, and expanding into new markets are critical strategies.
Sources
- U.S. Food & Drug Administration (FDA). Approved Drugs Database.
- IQVIA Institute. (2022). The Future of Biologic and Biosimilar Pricing.
- Medicare Payment Advisory Commission (MedPAC). (2021). Report to the Congress: Medicare Payment Policy.[1]
- EvaluatePharma. (2022). World Preview 2022: Outlook to 2027.
- PhRMA. (2021). Biopharmaceutical Pipeline Report.
In conclusion, pricing for NDC 62011-0468 will evolve based on patent status, competitive pressures, and policy landscapes. Stakeholders must continually adapt strategies aligned with market trends to optimize value.
More… ↓
